Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Hypoxic burden in men with obstructive sleep apnoea foretells heart failure

12 May 2020

The hypoxic burden associated with obstructive sleep apnoea (OSA) may predict the development of heart failure (HF) in men, a study has found.

The analysis included 4,881 middle-aged and older adults (mean age, 63.6 years; 54.4 percent female) from the Sleep Heart Health Study (SHHS) and 2,653 men (mean age, 76.2±5.4 years) from the Outcomes of Sleep Disorders in Older Men (MrOS). Overall, 7,534 individuals (20.1 percent) from both cohorts had moderate-to-severe OSA (apnoea-hypopnea index [AHI] ≥15).

Researchers computed the Sleep Apnea-Specific Hypoxic Burden (SASHB) as the sleep apnoea-specific area under the desaturation curve from pre-event baseline.

In the SHHS cohort, men had significantly higher mean SASHB (62.0 vs 37.0 %minute/hour; p<0.001) and AHI (11.0 vs 6.17 events/hour; p<0.001) compared with women. Over a mean follow-up of 10.4 years, 543 individuals developed HF, with the rate higher in men (11.9 vs 9.2 per 1,000 person-years for women) and increasing accordingly with higher AHI and SASHB.

In the MrOS cohort, 145 men developed HF over a mean follow-up of 8.8 years. The resulting incident rate was 6.05 per 1,000 person-years of follow-up, and this rose with increasing AHI and SASHB in the same way as in the SHHS cohort.

Multivariable Cox proportional hazard analysis revealed that SASHB predicted incident HF in men in both cohorts, whereas AHI did not. The resulting adjusted hazard ratios for HF per 1-SD increase in SASHB were 1.18 (95 percent confidence interval [CI, 1.02–1.37) in the SHHS cohort and 1.22 (95 percent CI, 1.02–1.45) in the MrOS cohort.

The association between HF and SASHB was observed in men with either low or high AHI levels. This was not seen in women.

“The findings suggest that quantification of an easily measured index of sleep apnoea-related hypoxias may be useful for identifying individuals at risk for heart disease while also suggesting targets for intervention,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, 28 Jul 2020
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Roshini Claire Anthony, 14 Sep 2020

Patients hospitalized with mild-to-moderate COVID-19 who are on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for hypertension should continue these medications, according to primary results of the BRACE CORONA trial presented at ESC 2020.

Tristan Manalac, 09 Jul 2020
Left ventricular assist devices (LVADs) trigger almost immediate favourable metabolic changes in both diabetics and nondiabetics, according to a recent study.
29 Mar 2020
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.